Showing posts with label cornea. Show all posts
Showing posts with label cornea. Show all posts

Tuesday, 6 October 2015

Restoring Vision with Stem Cells

Researchers have succeed in producing photoreceptors from human embryonic stem cells
Tuesday, 06 October 2015

Age-related macular degeneration (AMRD) could be treated by transplanting photoreceptors produced by the directed differentiation of stem cells, thanks to findings published today by Professor Gilbert Bernier of the University of Montreal and its affiliated Maisonneuve-Rosemont Hospital. ARMD is a common eye problem caused by the loss of cones. Bernier's team has developed a highly effective in vitro technique for producing light sensitive retina cells from human embryonic stem cells.

"Our method has the capacity to differentiate 80% of the stem cells into pure cones," Professor Gilbert explained.

"Within 45 days, the cones that we allowed to grow towards confluence spontaneously formed organised retinal tissue that was 150 microns thick. This has never been achieved before."

In order to verify the technique, Bernier injected clusters of retinal cells into the eyes of healthy mice. The transplanted photoreceptors migrated naturally within the retina of their host.

Age-related macular degeneration could be
treated by transplanting photoreceptors
produced by the directed differentiation of stem
cells, thanks to findings published today by
Professor Gilbert Bernier of the University of
Montreal and its affiliated Maisonneuve-
Rosemont Hospital. This image illustrates the 3D
reconstruction of the tissue that was produced in
vitro and labelled with antibodies against
photoreceptor-specific proteins. Credit: G.
Bernier, Université de Montréal.
"Cone transplant represents a therapeutic solution for retinal pathologies caused by the degeneration of photoreceptor cells," Bernier explained.

"To date, it has been difficult to obtain great quantities of human cones."

His discovery offers a way to overcome this problem, offering hope that treatments may be developed for currently non-curable degenerative diseases, like Stargardt disease and ARMD.

"Researchers have been trying to achieve this kind of trial for years," he said.

"Thanks to our simple and effective approach, any laboratory in the world will now be able to create masses of photoreceptors. Even if there's a long way to go before launching clinical trials, this means, in theory, that will be eventually be able to treat countless patients."

The findings are particularly significant in the light of improving life expectancies and the associated increase in cases of ARMD. ARMD is in fact the greatest cause of blindness amongst people over the age of 50 and affects millions of people worldwide. And as we age, it is more and more difficult to avoid - amongst people over 80, this accelerated aging of the retina affects nearly one in four. People with ARMD gradually lose their perception of colours and details to the point that they can no longer read, write, watch television or even recognize a face.

ARMD is due to the degeneration of the macula, which is the central part of the retina that enables the majority of eyesight. This degeneration is caused by the destruction of the cones and cells in the retinal pigment epithelium (RPE), a tissue that is responsible for the reparation of the visual cells in the retina and for the elimination of cells that are too worn out. However, there is only so much reparation that can be done as we are born with a fixed number of cones. They therefore cannot naturally be replaced. Moreover, as we age, the RPE's maintenance is less and less effective - waste accumulates, forming deposits.

"Differentiating RPE cells is quite easy. But in order to undertake a complete therapy, we need neuronal tissue that links all RPE cells to the cones. That is much more complex to develop," Bernier explains, noting nonetheless that he believes his research team is up to the challenge.

Bernier has been interested in the genes that code and enable the induction of the retina during embryonic development since completing his PhD in Molecular Biology in 1997.

"During my post-doc at the Max-Planck Institute in Germany, I developed the idea that there was a natural molecule that must exist and be capable of forcing embryonic stem cells into becoming cones," he said.

Indeed, bioinformatics analysis led him to predict the existence of a mysterious protein: COCO, a "recombinational" human molecule that is normally expressed within photoreceptors during their development.

In 2001, he launched his laboratory at Maisonneuve-Rosemont Hospital and immediately isolated the molecule. But it took several years of research to demystify the molecular pathways involved in the photoreceptors development mechanism. His latest research shows that in order to create cones, COCO can systematically block all the signalling pathways leading to the differentiation of the other retinal cells in the eye. It's by uncovering this molecular process that Bernier was able to produce photoreceptors. More specifically, he has produced S-cones, which are photoreceptor prototypes that are found in the most primitive organisms.

Beyond the clinical applications, Professor Bernier's findings could enable the modelling of human retinal degenerative diseases through the use of induced pluripotent stem cells, offering the possibility of directly testing potential avenues for therapy on the patient's own tissues.

Contact: William Raillant-Clark

Reference:
Differentiation of human embryonic stem cells into cone photoreceptors through simultaneous inhibition of BMP, TGFβ and Wnt signaling
Shufeng Zhou, Anthony Flamier, Mohamed Abdouh, Nicolas Tétreault, Andrea Barabino, Shashi Wadhwa and Gilbert Bernier
Development, 42, 3294-3306, October 1, 2015, doi: 10.1242/dev.125385
.........


For more on stem cells and cloning, go to CellNEWS at

Tuesday, 6 March 2012

Stem Cells Can Repair a Damaged Cornea

Stem Cells Can Repair a Damaged Cornea  
Tuesday, 06 March 2012


This is Charles Hanson. Credit:
University of Gothenburg.
A new cornea may be the only way to prevent a patient going blind – but there is a shortage of donated corneas and the queue for transplantation is long. Scientists at the Sahlgrenska Academy at the University of Gothenburg, Sweden, have for the first time successfully cultivated stem cells on human corneas, which may in the long term remove the need for donators.

Approximately 500 corneal transplantations are carried out each year in Sweden, and about 100,000 in the world. The damaged and cloudy cornea that is turning the patient blind is replaced with a healthy, transparent one. But the procedure requires a donated cornea, and there is a severe shortage of donated material. This is particularly the case throughout the world, where religious or political views often hinder the use of donated material.

Replacing donated corneas
Scientists at the Sahlgrenska Academy, University of Gothenburg, have taken the first step towards replacing donated corneas with corneas cultivated from stem cells. Scientists Charles Hanson and Ulf Stenevi have used defective corneas obtained from the ophthalmology clinic at Sahlgrenska University Hospital in Mölndal. Their study is now published in the journal Acta Ophthalmologica, and shows how human stem cells can be caused to develop into what are known as "epithelial cells" after 16 days' culture in the laboratory and a further 6 days' culture on a cornea. It is the epithelial cells that maintain the transparency of the cornea.

First time ever on human corneas
"Similar experiments have been carried out on animals, but this is the first time that stem cells have been grown on damaged human corneas. It means that we have taken the first step towards being able to use stem cells to treat damaged corneas", says Charles Hanson.

"If we can establish a routine method for this, the availability of material for patients who need a new cornea will be essentially unlimited. Both the surgical procedures and the aftercare will also become much more simple", says Ulf Stenevi.

Few clinics conduct transplants
Only a few clinics are currently able to transplant corneas. Many of the transplantations in Sweden are carried out at the ophthalmology clinic at Sahlgrenska University Hospital, Department of Ophthalmology, Mölndal.

Contact: Charles Hanson

Reference:
Transplantation of human embryonic stem cells onto a partially wounded human cornea in vitro
Charles Hanson, Thorir Hardarson, Catharina Ellerström, Markus Nordberg, Gunilla Caisander, Mahendra Rao, Johan Hyllner, Ulf Stenevi
Acta Ophthalmologica on 27 January, DOI: 10.1111/j.1755-3768.2011.02358.x
.........



For more on stem cells and cloning, go to CellNEWS at
http://cellnews-blog.blogspot.com/

Wednesday, 9 December 2009

Umbilical Stem Cells May Help Recover Lost Vision for Those With Corneal Disease

Umbilical Stem Cells May Help Recover Lost Vision for Those With Corneal Disease Wednesday, 09 December 2009 Winston Whei-Yang Kao, PhD, professor of ophthalmology at the University of Cincinnati.New research from the University of Cincinnati (UC) may help in the recovery of lost vision for patients with corneal scarring. Winston Whei-Yang Kao, PhD, professor of ophthalmology, along with other researchers in UC's ophthalmology department found that transplanting human umbilical mesenchymal stem cells into mouse models that lack the protein lumican restored the transparency of cloudy and thin corneas. Mesenchymal stem cells are "multi-potent" stem cells that can differentiate into a variety of cell types. These findings are being presented Dec. 8 in San Diego at the 49th Annual Meeting of the American Society for Cell Biology. "Corneal transplantation is currently the only true cure for restoration of eyesight that may have been lost due to corneal scarring caused by infection, mechanical and chemical wounds and congenital defects of genetic mutations," Kao says. "However, the number of donated corneas suitable for transplantation is decreasing as the number of individuals receiving refractive surgeries, like LASIK, increases." "Worldwide, there is a shortage of suitable corneas for transplantation, and at the present time, there is no effective alternative procedure besides corneal transplantation to treat corneal blindness," he continues. "There is a large need to develop alternative treatment regimens, one of which may be the transplantation of mesenchymal stem cells." Researchers used mouse models that did not have the lumican gene, also known as lumican knock-out models. Lumican is a protein that controls the formation and maintenance of transparent corneas. "Lumican knock-out models manifested thin and cloudy corneas," he says. "Transplantation of the umbilical stem cells significantly improved transparency and increased corneal stromal thickness in these mice." In addition, Kao says, the umbilical mesenchymal stem cells survived in the mouse stroma (connective tissue) for more than three months with minimal or no rejection and became corneal cells, repairing lost functions caused by mutations. "Our results suggest a potential treatment regimen for congenital and/or acquired corneal diseases," he says, adding that the availability of human umbilical stem cells is almost unlimited. "These stem cells are easy to isolate and can be recovered quickly from storage when treating patients.” "These findings have the potential to create new and better treatments — and an improved quality of life — for patients with vision loss due to corneal injury." ......... ZenMaster


For more on stem cells and cloning, go to CellNEWS at http://cellnews-blog.blogspot.com/

Thursday, 9 April 2009

Stem Cell Therapy Makes Cloudy Corneas Clear

Stem Cell Therapy Makes Cloudy Corneas Clear Thursday, 09 April 2009 Stem cells collected from human corneas restore transparency and don't trigger a rejection response when injected into eyes that are scarred and hazy, according to experiments conducted in mice by researchers at the University of Pittsburgh Schools of Medicine. Their study will be published in the journal Stem Cells and appears online today. The findings suggest that cell-based therapies might be an effective way to treat human corneal blindness and vision impairment due to the scarring that occurs after infection, trauma and other common eye problems, said senior investigator James L. Funderburgh, Ph.D., associate professor, Department of Ophthalmology. The Pitt corneal stem cells were able to remodel scar-like tissue back to normal. "Our experiments indicate that after stem cell treatment, mouse eyes that initially had corneal defects looked no different than mouse eyes that had never been damaged," Dr. Funderburgh said. The ability to grow millions of the cells in the lab could make it possible to create an off-the-shelf product, which would be especially useful in countries that have limited medical and surgical resources but a great burden of eye disease due to infections and trauma. "Corneal scars are permanent, so the best available solution is corneal transplant," Dr. Funderburgh said. "Transplants have a high success rate, but they don't last forever. The current popularity of LASIK corrective eye surgery is expected to substantially reduce the availability of donor tissue because the procedure alters the cornea in a way that makes it unsuitable for transplantation." A few years ago, Dr. Funderburgh and other University of Pittsburgh researchers identified stem cells in a layer of the cornea called the stroma, and they recently showed that even after many rounds of expansion in the lab, these cells continued to produce the biochemical components, or matrix, of the cornea. One such protein is called lumican, which plays a critical role in giving the cornea the correct structure to make it transparent. Mice that lack the ability to produce lumican develop opaque areas of their corneas comparable to the scar tissue that human eyes form in response to trauma and inflammation, Dr. Funderburgh said. But three months after the lumican-deficient mouse eyes were injected with human adult corneal stem cells, transparency was restored. The cornea and its stromal stem cells themselves appear to be "immune privileged," meaning they do not trigger a significant immune response even when transplanted across species, as in the Pitt experiments. "Several kinds of experiments indicated that the human cells were alive and making lumican, and that the tissue had rebuilt properly," Dr. Funderburgh noted. In the next steps, the researchers intend to use the stem cells to treat lab animals that have corneal scars to see if they, too, can be repaired with stem cells. Under the auspices of UPMC Eye Center's recently established Center for Vision Restoration, they plan also to develop the necessary protocols to enable clinical testing of the cells. ......... ZenMaster


For more on stem cells and cloning, go to CellNEWS at http://cellnews-blog.blogspot.com/ and http://www.geocities.com/giantfideli/index.html